GlassScriptPhysician profile
Gerald S Rothman
NPI 1164489977
$4,950.97
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,531 · 2020: $862 · 2022: $214 · 2023: $1,088 · 2024: $1,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,344.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,446.17 | 2019-2024 | Linzess, Viberzi, Creon |
| Janssen Biotech, INC. | $503.02 | 2019-2024 | Stelara, Tremfya, Simponi Aria |
| Allergan, INC. | $397.06 | 2019 | |
| Ironwood Pharmaceuticals, INC | $388.68 | 2020-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $363.99 | 2019-2024 | Xifaxan, Trulance |
| Pfizer INC. | $278.41 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $250.81 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $239.22 | 2019 | |
| Evoke Pharma, INC. | $184.82 | 2023 | Gimoti |
| Regeneron Healthcare Solutions, INC. | $183.94 | 2023-2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $166.01 | 2024 | Voquezna |
| Celgene Corporation | $131.39 | 2023-2024 | Zeposia |
| Gilead Sciences, INC. | $78.71 | 2019-2023 | |
| Concordia Pharmaceuticals INC. | $62.61 | 2019 | |
| Intercept Pharmaceuticals, INC. | $61.29 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $53.78 | 2023 | |
| Ardelyx, INC. | $34.66 | 2024 | Ibsrela |
| Braintree Laboratories, INC. | $31.16 | 2020 | |
| Ucb, INC. | $25.34 | 2019 | |
| Merck Sharp & Dohme LLC | $22.63 | 2024 | Dificid |
| Capsovision, INC. | $21.02 | 2023 | Capsocam Plus |
| Alfasigma USA, INC. | $14.00 | 2020 | |
| Ferring Pharmaceuticals INC. | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Rothman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.